We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMainz Biomed BV

Mainz Biomed BV

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-04-16T21:05:10.219318Z
Market Cap
16.63M

Momentum Score

…

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.55
Low
6.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.90M
Revenue Per Share
0.06
Gross Profit TTM
0.18M
Debt / Equity
2.28
ROE
-303.20%
Net Debt
0.35M
ROCE
-424.08%
Diluted EPS TTM
-2.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -26.39M -11.70M -0.59M -0.96M
Net income -26.45M -12.07M -0.89M -1.17M
Selling general administrative 17.83M 8.45M 0.35M 0.39M
Selling and marketing expenses 4.98M 0.96M 0.11M 0.18M
Gross profit 0.18M 0.18M 0.12M -0.06M
Reconciled depreciation 0.38M 0.07M 0.06M 0.05M
Ebit -26.17M -9.38M -0.33M -0.92M
Ebitda -25.65M -9.27M -0.27M -0.68M
Depreciation and amortization 0.52M 0.11M 0.06M 0.24M
Operating income -26.17M -9.38M -0.33M -0.92M
Other operating expenses 26.70M 9.96M 0.85M 1.03M
Interest expense 0.29M 0.34M 0.27M 0.20M
Tax provision 0.00M 0.00M - 0.00M
Net interest income -0.29M -0.34M -0.27M -0.20M
Income tax expense 0.07M 0.38M 0.30M 0.22M
Total revenue 0.53M 0.58M 0.49M 0.28M
Total operating expenses 26.36M 9.56M 0.48M 0.69M
Cost of revenue 0.35M 0.40M 0.37M 0.34M
Total other income expense net -0.21M -2.32M -0.26M -0.04M
Net income from continuing ops -26.39M -11.70M -0.59M -0.96M
Net income applicable to common shares - -11.69M -0.59M -0.96M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 15.41M 20.24M 10.04M 0.67M 0.72M
Intangible assets 3.39M - - - -
Other current assets 0.94M 801.96M 863.91M 0.02M 0.02M
Total liab 12.16M 6.14M 3.68M 3.41M 2.67M
Total stockholder equity 3.25M 14.10M 6.36M -2.74M -1.95M
Other current liab 1.51M 1.58M 0.27M 0.19M 0.05M
Common stock 0.24M 0.16M 0.14M 0.11M 0.11M
Capital stock 0.24M 0.16M 0.14M 0.11M 0.11M
Retained earnings -69.33M -43.03M -16.64M -4.95M -4.37M
Cash 7.07M 17.14M 8.73M 0.12M 0.20M
Total current liabilities 9.24M 4.24M 1.35M 0.70M 0.46M
Current deferred revenue 0.14M - - 0.00M 0.00M
Net debt 0.35M -13.91M -6.15M 2.86M 2.21M
Short term debt 5.22M 1.33M 0.25M 0.27M 0.21M
Short long term debt 4.94M 1.04M 0.19M 0.22M 0.17M
Short long term debt total 7.42M 3.23M 2.58M 2.98M 2.41M
Other stockholder equity 51.51M 38.83M 13.13M 2.11M -
Property plant equipment - - 0.43M 0.49M -
Total current assets 8.98M 18.38M 9.61M 0.19M 0.26M
Net tangible assets - - 6.36M -2.74M -
Net receivables 0.35M 0.26M 0.11M 0.04M 0.04M
Long term debt 1.03M 0.94M 1.94M 0.45M 0.37M
Inventory 0.61M 0.18M -863.14M - -
Accounts payable 2.36M 1.33M 0.83M 0.25M 0.20M
Accumulated other comprehensive income 20.83M 18.13M 9.74M 2.11M 2.31M
Non currrent assets other 0.00M 0.02M - - -
Non current assets total 6.43M 1.86M 0.43M 0.49M 0.46M
Capital lease obligations 1.45M 1.24M 0.44M 0.50M 0.45M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.66M 1.20M -0.01M 0.00M
Change to liabilities 0.00M 0.67M 0.16M 0.08M
Total cashflows from investing activities - 1.20M -0.01M -0.01M
Net borrowings - 0.19M 0.40M 0.42M
Total cash from financing activities 23.94M 10.61M 0.40M 0.42M
Change to operating activities - -0.83M -0.00M 0.00M
Net income -26.39M -11.69M -0.59M -0.96M
Change in cash 8.41M 8.60M -0.08M -0.03M
Begin period cash flow 8.73M 0.12M 0.20M 0.23M
End period cash flow 17.14M 8.73M 0.12M 0.20M
Total cash from operating activities -14.77M -3.22M -0.47M -0.42M
Issuance of capital stock 23.87M 10.43M - 0.00M
Depreciation 0.38M 0.07M 0.06M 0.05M
Change to inventory -0.17M -670.73M - -
Change to account receivables - 0.02M -0.10M 0.34M
Other cashflows from financing activities 0.38M 0.25M 0.44M 0.45M
Change to netincome 9.85M 8.40M -0.09M 0.02M
Capital expenditures 0.66M 0.02M 0.01M 0.01M
Change in working capital 1.39M -0.14M 0.06M 0.42M
Stock based compensation 9.82M 6.43M - 0.00M
Other non cash items 0.03M 2.11M 0.00M 0.06M
Free cash flow -15.43M -3.24M -0.48M -0.42M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TMO
Thermo Fisher Scientific Inc		 -15.12
2.11%		 702.59 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -1.34
0.57%		 233.97 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 24.91 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.17
0.68%		 24.93 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Mainz Biomed BV

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

Robert Koch Strasse 50, Mainz, Germany, 55129

49 6131 554 2860

https://mainzbiomed.com

65

Name Title Year Born
Mr. Guido Baechler CEO & Director 1965
Mr. William J. Caragol Chief Financial Officer 1967
Mr. Philipp Freese Chief Operating Officer 1983
Dr. Moritz Eidens Ph.D. Chief Science Officer & Director 1984
Mr. Darin S. Leigh Chief Commercial Officer NA
Mr. Guido Baechler CEO & Executive Director 1965
Dr. Christopher Von Torne P.M.P., Ph.D. Chief Operating Officer 1972
Dr. Frank Krieg-Schneider Chief Technology Officer 1962
Dr. Moritz Eidens Ph.D. Chief Science Officer & Executive Director 1984
Stefan Erlach Head of Human Resources NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…